Sansrosa (brimonidine)

[Guide]

Galderma Pharmaceuticals has announced positive results from a phase 3 trial of CD07805/47, a proprietary topical gel for rosacea. For more info. Dr. Fowler who is the principal study investigator of this phase 2B is also a member of the RRDi MAC.

 More info:
http://www.medicalne...cles/236391.php

Background info:

Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment of moderate to severe facial erythema of rosacea: results of two multicenter, randomized and vehicle-controlled studies.
Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M; on behalf of the Brimonidine Phase II study group.
Br J Dermatol. 2011 Nov 2. doi: 10.1111/j.1365-2133.2011.10716.x.
The information on this as of September 2012.

Sansrosa became known as Mirvaso. [1]

End Notes

[1] Mirvaso (Sansrosa, Brimonidine) Approved for Rosacea Redness, RSG